Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan–Meier Curves with Trial Sequential Analysis-Reference-Cited by-同舟云学术

Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan–Meier Curves with Trial Sequential Analysis

Published:2024-07-04 Issue:5 Volume:24 Page:629-640
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Soliman Youssef^ORCID,Abuelazm Mohamed,Amer Basma Ehab,Hukamdad Mishaal,Ellabban Mohamed Hatem,Hendi Nada Ibrahim,Mouffokes Adel,AbdelAzeem Basel,Hassaballa Hatem

Funder

Assiut University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40256-024-00661-5.pdf

Reference36 articles.

1. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56–62. https://doi.org/10.1016/J.AMJCARD.2011.03.004.

2. Dublin S, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25(8):853–8. https://doi.org/10.1007/S11606-010-1340-Y/FIGURES/2.

3. Kubota Y, Shimizu W. Clinical benefits of sodium-glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects. JACC Asia. 2022;2(3P2):287–93. https://doi.org/10.1016/J.JACASI.2022.03.009.

4. Mouffokes A, Soliman Y, Amer BE, Umar TP, Abdelazeem B. Abstract 13815: therapeutic effects of empagliflozin in diabetic patients after acute myocardial infarction: systematic review and meta-analysis with trial sequential analysis. Circulation (New York, N Y). 2023. https://doi.org/10.1161/circ.148.suppl_1.13815.

5. Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(2):E145–52. https://doi.org/10.1097/FJC.0000000000001183.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-Glucose Cotransporter-2 Inhibitors: Elevating Standards in Cardiovascular Secondary Prevention;American Journal of Cardiovascular Drugs;2024-07-17